Manuscripts
Scientific manuscripts are developed in collaboration with key experts and are published in peer-reviewed journals.
)
This page is intended as an educational resource for U.S. healthcare professionals. The list of Acadia-sponsored manuscripts below may contain information about doses, uses, formulations, and populations different from product labeling or contain information about investigational compounds or uses not approved by the FDA. Please refer to the product’s Full Prescribing Information.
An Open-Label Study Investigating the 5-HT2A Receptor Occupancy of Remlifanserin (ACP-204) With the PET Radioligand [18F]Altanserin in Healthy Male Participants
Clinical Pharmacology in Drug Development
Compatibility of trofinetide with ketogenic diets in patients with rett syndrome: case reports
Future Rare Diseases
Discovery of novel SSRIs for a combination-treatment with pimavanserin
Bioorganic & Medical Chemistry Letters
Nonclinical Characterization of ACP-204, a Novel Selective 5-HT2A Receptor Inverse Agonist
The Journal of Pharmacology and Experimental Therapeutics
Population pharmacokinetics of remlifanserin (ACP-204), a serotonin 2A receptor inverse agonist
Alzheimer’s & Dementia: Translational Research & Clinical Interventions
A global literature review of comorbidities and concomitant supportive medications among individuals with Rett syndrome
Journal of Comparative Effectiveness Research
Characteristics of adult individuals with Rett syndrome treated or untreated with trofinetide in the United States
Frontiers in Neurology
Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader–Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 COMPASS PWS Study
Clinical Therapeutics
Real‑World Demographics, Clinical Characteristics, and Predictors of Persistence Among Males with Rett Syndrome Treated with Trofinetide
Advances in Therapy
Trofinetide Use and Treatment Patterns Among Children Aged 2–4 Years with Rett Syndrome in the United States: A Retrospective Specialty Pharmacy Linked Claims Database Analysis
International Journal of General Medicine
Rett syndrome and real-world treatment patterns of trofinetide in the United States
Journal of Medical Economics
Real-World Treatment Landscape of Individuals with Rett Syndrome Treated and Untreated with Trofinetide in the United States
Journal of Health Economics and Outcomes Research
Utilization of Non‑pharmacological Interventions in Rett Syndrome: A Systematic Review of the Literature on Supportive Care Management
Neurology and Therapy
Falls and fractures among long–term careresidents with Parkinson’s disease psychosistreated with pimavanserin versus other atypicalantipsychotics: a plain language summary
Future Neurology
Impact of Early Treatment with Pimavanserin on Health Care Resource Utilization Among Newly Diagnosed Patients with Parkinson’s Disease Psychosis: A Pre-Post Medicare Claims Database Analysis
Journal of Health Economics and Outcomes Research
Real-world evidence of pimavanserin utilization among patients with Parkinson’s disease psychosis: a review of real-world data that augments data from randomized controlled trials
Journal of Comparative Effectiveness Research
Safety and Efficacy of Pimavanserin in Patients With Lewy Body Dementia Experiencing Dementia-Related Psychosis in the HARMONY Study
BMC Neurology
Expert Consensus on Real-World Use of Trofinetide for Rett Syndrome Using a Modified Delphi Method
Annals of Child Neurology
A Phase 1, Randomized, Open-Label Study to Assess the Bioequivalence of Trofinetide as a Ready-to-Use Oral Solution and Constituted Powder for Oral Solution in Healthy Adults.
Advances in Therapy
Real-world use of trofinetide: a survey of practices from prescribers at Rett syndrome centers of excellence in the United States
Future Rare Diseases
Real-world benefits and tolerability of trofinetide for the treatment of Rett syndrome: The LOTUS study
Developmental Medicine & Child Neurology
5-HT2A receptor inverse agonist attenuates morphine withdrawal syndrome and its aversiveness in rats
Behavioural Pharmacology
The Modified Functional Status Questionnaire for Assessing Patients with Parkinson’s Disease Psychosis Treated with Pimavanserin: A Post Hoc Analysis
Neurology and Therapy
Managing gastrointestinal comorbidities with or without trofinetide use in Rett syndrome: a plain language summary
Future Rare Diseases
Sedation and sleep safety of pimavanserin for Parkinsons’s disease psychosis: Review and exploratory analysis of clinical study data
Clinical Parkinsonism & Related Disorders
Long-Term Outcomes in a Parkinson's Disease Minor Phenomena Cohort
Movement Disorders Clinical Practice
Healthcare resource utilization patterns among patients with Parkinson’s disease psychosis and dementia: analysis of US Medicare beneficiaries treated with pimavanserin versus other-atypical antipsychotics or versus quetiapine
Journal of Medical Economics
Management of Parkinson’s disease psychosis: firstline antipsychotic selection and rationale for continuing, combining, or switching
Expert Opinion on Pharmacotherapy
Results from the phase 2/3 DAFFODIL study of trofinetide in girls aged 2-4 years with Rett syndrome
Med
Plain language summary of mortality rates of patients with Parkinson’s disease psychosis who were treated either with pimavanserin or with different second-generation (atypical) antipsychotics
Future Neurology
Assessing Experiences With Trofinetide for Rett Syndrome: Interviews With Caregivers of Participants in Clinical Trials
Clinical Therapeutics
Assessing the effects of trofinetide on QTc interval, safety and tolerability, and pharmacokinetics in healthy adults
Future Rare Diseases
Healthcare resource utilization patterns among patients with Parkinson’s disease psychosis: Analysis of individuals covered by Medicare and treated with pimavanserin or other atypical antipsychotics
Future Neurology
Plain Language Summary of Publication: Healthcare resource utilization patterns among patients with Parkinson’s disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other atypical antipsychotics
Future Neurology
Trofinetide benefits the ability to communicate in Rett syndrome: a plain language summary of the LAVENDER trial
Future Rare Diseases
Characterizing the journey of Rett syndrome among females in the United States: a real-world evidence study using the Rett syndrome natural history study database
Journal of Neurodevelopmental Disorders
Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study
Med
Improvement in symptoms of Rett syndrome with trofinetide beyond clinical trial efficacy assessments: case reports
Future Rare Diseases
Effect of Hepatic Impairment on Trofinetide Exposures Using an In Silico Physiologically Based Pharmacokinetic Model
Advances in Therapy
Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study
Med
Recommendations for the management of gastrointestinal comorbidities with or without trofinetide use in Rett syndrome
Expert Review of Gastroenterology & Hepatology
Analysis of Medicare patients treated with pimavanserin versus other atypical antipsychotics: a cost-offset model evaluating skilled nursing facility stays and long-term care admissions in Parkinson’s disease psychosis
ClinicoEconomics and Outcomes Research
The effects of treatment with pimavanserin on activities of daily living in subjects with Parkinson’s disease psychosis (PDP): a 16-week open-label study
Therapeutic Advances in Neurological Disorders
Safety profile of pimavanserin therapy in elderly patients with neurodegenerative disease-related neuropsychiatric symptoms: a phase 3B study
Journal of Alzheimer's Disease
Trofinetide treatment demonstrates a benefit over placebo for the ability to communicate in Rett syndrome
Pediatric Neurology
Managing gastrointestinal symptoms resulting from treatment with trofinetide for Rett syndrome: caregiver and nurse perspectives
Advances in Therapy
Exposure-response efficacy modeling to support trofinetide dosing in individuals with Rett syndrome
Advances in Therapy
A physiologically based pharmacokinetic modeling approach to assess the potential for drug interactions between trofinetide and CYP3A4 metabolized drugs
Clinical Therapeutics
Pimavanserin for psychosis in Parkinson’s disease dementia: subgroup analysis of the HARMONY trial
Parkinsonism & Related Disorders
Development of trofinetide for the treatment of Rett syndrome from bench to bedside
Frontiers in Pharmacology
Risk of long-term care admissions among Medicare beneficiaries treated with pimavanserin or quetiapine for Parkinson’s disease psychosis in the US: a retrospective administrative claims data base analysis
Journal of Comparative Effectiveness Research
Characterization of the pharmacokinetics and mass balance of a single oral dose of trofinetide in healthy male subjects
Clinical Drug Investigation
Gastrointestinal manifestations in pediatric and adult patients with Rett syndrome: an analysis of US claims and physician survey data
Journal of Comparative Effectiveness Research
Incremental health care resource utilization and costs associated among patients with Parkinson’s disease psychosis and incident dementia: an analysis of Medicare beneficiaries
International Journal of Geriatric Psychiatry
A plain language summary of results from the LAVENDER study: trofinetide treatment for Rett syndrome
Future Rare Diseases
A review of the Rett Syndrome Behaviour Questionnaire and its utilization in the assessment of symptoms associated with Rett syndrome
Frontiers in Pediatrics
Patients treated with pimavanserin or quetiapine for Parkinson’s disease psychosis: analysis of health resource utilization patterns among Medicare beneficiaries
Journal of Medical Economics
Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study
Nature Medicine
Meaningful improvements in Rett syndrome: a qualitative study of caregivers
Journal of Child Neurology
Exposure-response modeling from the CLARITY trial of pimavanserin for adjunctive treatment of major depressive disorder
Clinical Pharmacology in Drug Development
Epidemiology and patient journey of Rett Syndrome in the United States: a real-world evidence study
BMC Neurology
Mortality in patients with Parkinson’s disease-related psychosis treated with pimavanserin compared with other atypical antipsychotics: a cohort study
Drug Safety
Pimavanserin reverses multiple measures of anxiety in a rodent model of post-traumatic stress disorder
European Journal of Pharmacology
Characteristics, conditions, and healthcare service utilization patterns of individuals diagnosed with Rett syndrome: an analysis of administrative claims data
Future Rare Diseases
Recommendations for managing diarrhea from trofinetide use with Rett syndrome: a plain language summary
Future Rare Diseases
Health care resource utilization patterns among patients with Parkinson’s disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics
Journal of Medical Economics
Mortality risk in patients with Parkinson’s disease-related psychosis treated with pimavanserin compared with other atypical antipsychotics: a cohort study
Drug Safety
Adjunctive pimavanserin in patients with major depressive disorder: combined results from two randomized, double-blind, placebo-controlled, phase 3 studies
Psychopharmacology Bulletin
Motor- and cognition-related safety of pimavanserin in patients with Parkinson’s disease psychosis
Frontiers in Neurology
Role of pimavanserin treatment-continuity on discharge from long-term care: assessing the quality of antipsychotic medication review
Senior Care Pharmacist
Hallucinations and delusions associated with Parkinson’s disease psychosis: safety of current treatments and future directions
Expert Opinion on Drug Safety
Screening, diagnosis, and management of Parkinson’s disease psychosis: recommendations from an expert panel
Neurology and Therapy
Using telemedicine to assess and manage psychosis in neurodegenerative diseases in long-term care
Journal of the American Medical Directors Association
Incidence, prevalence, and mortality of psychosis associated with Parkinson disease (1991-2010)
Journal of Parkinson’s Disease
Pimavanserin augments the efficacy of atypical antipsychotic drugs in a mouse model of treatment-refractory negative symptoms of schizophrenia
Behavioural Brain Research
Impact of isolation during the COVID-19 pandemic on the patient burden of Parkinson’s disease: a PMD Alliance survey
Neuropsychiatric Disease and Treatment
In vitro stability and recovery studies of pimavanserin in water and in different vehicles orally administered
Drugs in R&D
Falls and fractures in patients with Parkinson’s disease-related psychosis treated with pimavanserin vs atypical antipsychotics: a cohort study
Drugs - Real World Outcomes
Dementia-related psychosis and the potential role for pimavanserin
Dementia-related psychosis and the potential role for pimavanserin
Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome
Contemporary Clinical Trials
The impact of pimavanserin on psychotic phenotypes and tau phosphorylation in the P301L/COMT– and rTg(P301L)4510 mouse models of Alzheimer’s disease
Alzheimer’s & Dementia
Treatment patterns with antipsychotics in long-term care patients with Parkinson’s disease psychosis
Journal of Applied Gerontology
Comparative efficacy, safety, tolerability, and effectiveness of antipsychotics in the treatment of dementia-related psychosis (DRP): a systematic literature review
The Journal of Prevention of Alzheimer's Disease
Trial of pimavanserin in dementia-related psychosis
The New England Journal of Medicine
Relevance of 5-HT2A receptor modulation of pyramidal cell excitability for dementia-related psychosis: implications for pharmacotherapy
CNS Drugs
Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson’s disease psychosis patients
Parkinsonism & Related Disorders
Pimavanserin promotes trophic factor release and protects cultured primary dopaminergic neurons exposed to MPP+ in a GDNF-dependent manner
ACS Chemical Neuroscience
Real-world medication treatment patterns for long-term care residents with dementia-related psychosis
Gerontology and Geriatric Medicine
Burden of illness among patients with dementia-related psychosis
Journal of Managed Care & Specialty Pharmacy
Association of dementia-related psychosis with long-term care use and death
Neurology
Increased risk of falls and fractures in patients with psychosis and Parkinson disease
PLoS One
Pimavanserin, a 5HT 2A receptor inverse agonist, rapidly suppresses Aβ production and related pathology in a mouse model of Alzheimer’s disease
Journal of Neurochemistry
Pimavanserin treatment for Parkinson’s disease psychosis in clinical practice
Parkinson’s Disease
Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: analysis of the CLARITY study
Journal of Affective Disorders
Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer’s disease psychosis: a post hoc analysis
International Journal of Geriatric Psychiatry
Blinded SAPS-PD assessment after 10 weeks of pimavanserin treatment for Parkinson’s disease psychosis
Journal of Parkinson’s Disease
An open-label, 8-week study of safety and efficacy of pimavanserin treatment in adults with Parkinson’s disease and depression
Journal of Parkinson’s Disease
Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the CLARITY study
International Clinical Psychopharmacology
Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson’s disease psychosis
Parkinsonism & Related Disorders
Improvement of sexual function during treatment of major depressive disorder with adjunctive pimavanserin: a secondary analysis
Depression and Anxiety
Inverse agonists of the 5-HT2A receptor reduce nicotine withdrawal signs in rats
Neuroscience Letters
Increases in institutionalization, healthcare resource utilization, and mortality risk associated with Parkinson disease psychosis: retrospective cohort study
Parkinsonism & Related Disorders
A phase 2, randomized, double-blind, placebo-controlled study of adjunctive pimavanserin in patients with major depressive disorder and an inadequate response to therapy (CLARITY)
The Journal of Clinical Psychiatry
Impact of non-motor symptoms in Parkinson’s disease: a PMDAlliance survey
Neuropsychiatric Disease and Treatment
Changing the treatment paradigm for Parkinson’s disease psychosis with pimavanserin
Expert Review of Clinical Pharmacology
Double-blind, randomized, placebo‐controlled study of trofinetide in pediatric Rett syndrome
Neurology
Pimavanserin in Alzheimer’s disease psychosis: efficacy in patients with more pronounced psychotic symptoms.
The Journal of Prevention of Alzheimer's Disease
Nighttime sleep and daytime sleepiness improved with pimavanserin during treatment of Parkinson’s disease psychosis
Clinical Neuropharmacology
Pimavanserin for Parkinson’s disease psychosis: effects stratified by baseline cognition and use of cognitive-enhancing medications
Movement Disorders
Pimavanserin: potential treatment for dementia-related psychosis
The Journal of Prevention of Alzheimer's Disease
Pimavanserin for the treatment of Parkinson’s disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed
CNS Spectrums
Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study
Lancet Neurology
A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome
Pediatric Neurology
The emerging role of pimavanserin in the management of Parkinson’s disease psychosis
Journal of Managed Care & Specialty Pharmacy
Parkinson’s disease psychosis: symptoms, management, and economic burden
The American Journal of Managed Care
On the discovery and development of pimavanserin: a novel drug candidate for Parkinson’s psychosis
Neurochemical Research
Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial
Lancet
Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson’s disease and Parkinson’s disease psychosis: evaluation of therapeutic ratios
Behavioural Pharmacology
Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson’s disease psychosis
Parkinsonism & Related Disorders
Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer’s disease
Behavioural Pharmacology
Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson’s disease
Behavioural Pharmacology
Pimavanserin, a serotonin2A receptor inverse agonist, for the treatment of Parkinson’s disease psychosis
Neuropsychopharmacology
A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model
Pharmacology Biochemistry and Behavior
PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain
The International Journal of Neuropsychopharmacology
ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models
The Journal of Pharmacology and Experimental Therapeutics
Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N’-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine2A receptor inverse agonist
The Journal of Pharmacology and Experimental Therapeutics
Psychosis of Parkinson’s disease: serotonin 2A inverse agonists as potential therapeutics
Current Opinion in Investigational Drugs
127 Results